Jessica Kennard, DO
Gynecologic Oncology · Orlando, FLNPI 1225477607
Payments from drug & device makers
What this record shows
This record is dominated by education: $32,102 of the $38,640 with a category attached, or 83.1%. Intuitive Surgical accounts for 88.4% of it on its own, with 34 other manufacturers making up the rest. Reporting peaked in 2024 at $25,969 and has fallen 99.1% since, to $237 in 2025.
Across 144 payments — averaging $268.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$34K
- AstraZeneca$1K
- Baxter Healthcare$721
- Integra Lifesciences Corporation$290
- Immunogen, Inc.$255
- AbbVie$246
- plus $2K from 29 others
What the payments were for
- Travel & lodging$1210%
- Food & beverage$6,41617%
- Education$32,10283%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 36 | $34,163 |
| AstraZeneca | 24 | $1,125 |
| Baxter Healthcare | 14 | $721 |
| Integra Lifesciences Corporation | 4 | $290 |
| Immunogen, Inc. | 2 | $255 |
| AbbVie | 7 | $246 |
| Merck | 12 | $224 |
| Clovis Oncology, Inc. | 2 | $128 |
| Heron Therapeutics, Inc. | 1 | $128 |
| Eisai Inc. | 5 | $125 |
| Bayer | 1 | $125 |
| Medical Device Business Services, Inc. | 1 | $123 |
| Tesaro, Inc. | 1 | $115 |
| Johnson & Johnson | 2 | $115 |
| Tetraphase Pharmaceuticals, Inc. | 1 | $105 |
| Hologic Sales And Service, LLC | 2 | $77 |
| Sumitomo Pharma America, Inc. | 3 | $68 |
| GSK | 3 | $65 |
| Myriad Genetic Laboratories, Inc. | 3 | $63 |
| Fennec Pharmaceuticals, Inc. | 4 | $53 |
| Conmed Corporation | 1 | $33 |
| Avanos Medical | 1 | $31 |
| Meditrina | 2 | $31 |
| Organon | 1 | $25 |
| Astellas Pharma US Inc | 1 | $24 |
| Organogenesis Inc. | 1 | $24 |
| Eagle Pharmaceuticals, Inc. | 1 | $22 |
| Novartis | 1 | $22 |
| Kerecis Limited | 1 | $19 |
| Minerva Surgical, Inc | 1 | $19 |
| Daiichi Sankyo Inc. | 1 | $18 |
| Pharmacosmos Therapeutics Inc. | 1 | $18 |
| Medtronic | 1 | $15 |
| Mimedx Group, Inc. | 1 | $14 |
| Myovant Sciences Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$38,640 in reported general payments places this provider in the 80th percentile of 117 gynecologic oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 11 | $10,453 |
| Estradiol | 36 | $1,781 |
| Ondansetron Hcl | 12 | $751 |
| Letrozole | 20 | $322 |
| Clobetasol Propionate | 17 | $230 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 14 | $196 |
| Megestrol Acetate | 12 | $190 |
| Prochlorperazine Maleate | 15 | $160 |
| Oxycodone Hcl | 46 | $151 |
| Ibuprofen | 36 | $123 |
| Gabapentin | 11 | $122 |
| Tamoxifen Citrate | 11 | $28 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $115 | $10,45311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 117 gynecologic oncology providers in Florida.
Other gynecologic oncology in Orlando
- Robert HollowayOrlando$432K
- Shelly SewardOrlando$349K
- Nathalie McKenzieOrlando$223K
- Christopher BryantOrlando$28K
- Veronica SchimpOrlando$5K
- James KendrickOrlando$3K
- Bradley MonkWest Palm Beach$2.5M
- Martin MartinoJacksonville$957K
- Brian SlomovitzFort Lauderdale$519K
- Ricardo EstapeMiami$457K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.